In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Are target doses relevant for women with heart failure? - implications for sacubitril-valsartan

Session Patient management - From oral treatment to transplant

Speaker Helena Norberg

Congress : Heart Failure 2018

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure: Pharmacotherapy
  • Session type : Rapid Fire Abstracts
  • FP Number : 1543

Authors : HM Norberg (Umea,SE), V Pranic (Umea,SE), E Bergdahl (Umea,SE), K Lindmark (Umea,SE)


HM Norberg1 , V Pranic2 , E Bergdahl2 , K Lindmark2 , 1Umea University, Public Health and Clinical Medicine, Pharmacology and Clinical Neuroscience - Umea - Sweden , 2Umea University, Public Health and Clinical Medicine - Umea - Sweden ,


Background: In the PARADIGM-HF trial sacubitril-valsartan reduced both heart failure hospitalizations and cardiovascular death by 20% compared to enalapril. The proportion of women in the study was only 21%. Previous work has shown that in a community based heart failure population the proportion of women eligible for sacubitril-valsartan is only 16%. This is surprising since the total heart failure population is evenly distributed.

Purpose: To investigate why so few women are eligible for treatment with sacubitril-valsartan.

Methods: We applied the PARADIGM-HF main inclusion and exclusion criteria to a community based heart failure population in northern Sweden and statistically compared the women and men cohort.

Results: Of the whole heart failure population of 1924 patients, 43% were women. However, in patients with ejection fraction (EF) = 35%, only 28% were women and after applying the PARADIGM-HF main inclusion and exclusion criteria, only 15 women would have been eligible for inclusion in the trial, corresponding to 16% of the eligible patients. The most common reason for not meeting the criteria was failure to reach target dose of ACE inhibitor or ARB. In patients with heart failure and reduced ejection fraction (HFrEF) women were older (81.1 ± 10.6 vs. 74.8 ± 11.5, p < 0.001) had lower body weight (69.4 ± 17.2 vs. 85.3 ± 17.5, p < 0.001), lower estimated glomerular filtration rate (48.5 ± 26.2 vs. 70.1 ± 34.5, p < 0.001), and higher systolic blood pressure (127.4 ± 19.0 vs. 122.5 ± 18.5, p = 0.018). Besides fewer women reached target dose of ACE inhibitor or ARB (26% vs. 43%, p = 0.001), heart failure therapy did not differ between the genders except that women were more often prescribed loop-diuretics and less likely to have an implantable cardioverter defibrillator or cardiac resynchronization therapy defibrillator.

Conclusions: Fewer women suffer from HFrEF and tolerate target doses of ACE inhibitor or ARB, and are consequently less eligible for sacubitril-valsartan compared to men. Women probably tolerate target doses to a lesser degree owing to being older, having lower body weight (less volume of distribution), and lower renal function. Though, we cannot exclude that women are treated differently because of gender bias. This study shows that target doses as entry criteria in clinical trials favors men, which is important to consider in future study design to gain better knowledge of how to offer women with heart failure the best available care. Since current guideline recommended target doses are mainly based on men, we suggest more individualized doses to women with heart failure.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are